Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Semin Immunopathol. 2024 Jan;45(4-6):451-468. doi: 10.1007/s00281-023-00996-2. Epub 2023 Jul 12.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged late in 2019 and caused the coronavirus disease 2019 (COVID-19) pandemic that has so far claimed approximately 20 million lives. Vaccines were developed quickly, became available in the end of 2020, and had a tremendous impact on protection from SARS-CoV-2 mortality but with emerging variants the impact on morbidity was diminished. Here I review what we learned from COVID-19 from a vaccinologist's perspective.
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）于 2019 年末出现，引发了目前已导致约 2000 万人死亡的 2019 年冠状病毒病（COVID-19）大流行。疫苗的研发速度很快，于 2020 年末问世，对预防 SARS-CoV-2 死亡率产生了巨大影响，但随着新变种的出现，其对发病率的影响降低了。在此，我从疫苗学家的角度回顾了我们从 COVID-19 中学到的经验教训。
